Clinical Trials Logo

Breast Ductal Carcinoma in Situ clinical trials

View clinical trials related to Breast Ductal Carcinoma in Situ.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04022772 Completed - Breast Carcinoma Clinical Trials

Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

Start date: July 31, 2019
Phase: N/A
Study type: Interventional

This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer. PACK Health monitors breast cancer patients' reported side effects and experience of care when receiving chemotherapy. Participating in the PACK Health coaching program may improve quality of life, decrease hospital admissions and improve overall health.

NCT ID: NCT03323658 Completed - Clinical trials for Invasive Breast Carcinoma

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

Start date: June 15, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs that are called rexinoids, and it may reduce the incidence of breast tumors.

NCT ID: NCT02636582 Completed - Clinical trials for Breast Ductal Carcinoma In Situ

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Start date: June 14, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or sargramostim works in treating patients with breast cancer. Vaccines made from peptide or antigen and/or a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express breast cancer antigens. It is not yet known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in treating patients with breast cancer.